Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12872130 | 0.92 | HTR6 (0.71) | HTR6CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL8000310 | 0.90 | HTR6 (0.61) | HTR6CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL8000313 | 0.87 | HTR6 (0.55) | HTR6CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL13303316 | 0.86 | HTR6 (0.72) | HTR6CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL16269845 | 0.85 | HTR6 (0.55) | HTR6CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL12872129 | 0.85 | HTR6 (0.54) | HTR6CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL12872140 | 0.85 | HTR6 (0.57) | HTR6CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL1179300 | 0.84 | HTR6 (0.67) | HTR6CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL1179301 | 0.84 | HTR6 (0.67) | HTR6CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL16269846 | 0.83 | HTR6 (0.58) | HTR6CHRM2CHRM4HTR1ACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610247-B1 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LTD (BS) | 2016-05-25 | — | — | EP | disclosed |
| EP-2265589-B1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LTD (BS) | 2016-01-27 | — | — | EP | disclosed |
| US-9126942-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2015-09-08 | — | — | US | disclosed |
| US-9126942-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2015-09-08 | — | — | US | disclosed |
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LIMITED (BS) | 2015-02-19 | — | — | US | disclosed |
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LIMITED (BS) | 2015-02-19 | — | — | US | disclosed |
| US-8901108-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-8901108-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2014-01-09 | — | — | US | disclosed |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2014-01-09 | — | — | US | disclosed |
| US-8563723-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| US-8563723-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| EP-2610247-A1 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | Abbott Healthcare Products B.V. (NL) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HOSPITALS LIMITED (BS) | 2011-02-24 | — | — | US | disclosed |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HOSPITALS LIMITED (BS) | 2011-02-24 | — | — | US | disclosed |
| WO-2009115515-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885CHRM2 51/4885CHRM4 66/4885 |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885CHRM2 51/4885CHRM4 66/4885 |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885CHRM2 51/4885CHRM4 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.